MXPA02011194A - Inhibidores de aromatasa y anticuerpos anti-her2 monoclonales como agentes antitumorales. - Google Patents
Inhibidores de aromatasa y anticuerpos anti-her2 monoclonales como agentes antitumorales.Info
- Publication number
- MXPA02011194A MXPA02011194A MXPA02011194A MXPA02011194A MXPA02011194A MX PA02011194 A MXPA02011194 A MX PA02011194A MX PA02011194 A MXPA02011194 A MX PA02011194A MX PA02011194 A MXPA02011194 A MX PA02011194A MX PA02011194 A MXPA02011194 A MX PA02011194A
- Authority
- MX
- Mexico
- Prior art keywords
- her2
- aromatase inhibitor
- antibody against
- human
- against her2
- Prior art date
Links
- 239000003886 aromatase inhibitor Substances 0.000 title claims abstract description 40
- 230000000259 anti-tumor effect Effects 0.000 title claims description 11
- 229940046844 aromatase inhibitors Drugs 0.000 title description 7
- 239000003795 chemical substances by application Substances 0.000 title description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 23
- 230000001419 dependent effect Effects 0.000 claims abstract description 18
- 229940088597 hormone Drugs 0.000 claims abstract description 18
- 239000005556 hormone Substances 0.000 claims abstract description 18
- 230000002018 overexpression Effects 0.000 claims abstract description 14
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims abstract description 13
- 229960000255 exemestane Drugs 0.000 claims abstract description 13
- 230000002195 synergetic effect Effects 0.000 claims abstract description 12
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 10
- 229960002932 anastrozole Drugs 0.000 claims abstract description 9
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960000575 trastuzumab Drugs 0.000 claims abstract description 9
- 229960003881 letrozole Drugs 0.000 claims abstract description 6
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims abstract description 6
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229950011548 fadrozole Drugs 0.000 claims abstract description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract 15
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 5
- QXKJWHWUDVQATH-UHFFFAOYSA-N rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 229960004421 formestane Drugs 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 3
- 229960003437 aminoglutethimide Drugs 0.000 claims description 3
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 3
- 229950004810 atamestane Drugs 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 229960004125 ketoconazole Drugs 0.000 claims description 3
- 229960005353 testolactone Drugs 0.000 claims description 3
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 claims description 3
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 claims description 3
- 229960001670 trilostane Drugs 0.000 claims description 3
- 229960001771 vorozole Drugs 0.000 claims description 3
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229950005230 rogletimide Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 description 15
- 102000009465 Growth Factor Receptors Human genes 0.000 description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57135500A | 2000-05-15 | 2000-05-15 | |
| PCT/EP2001/004468 WO2001087334A1 (en) | 2000-05-15 | 2001-04-19 | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02011194A true MXPA02011194A (es) | 2003-03-10 |
Family
ID=24283360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02011194A MXPA02011194A (es) | 2000-05-15 | 2001-04-19 | Inhibidores de aromatasa y anticuerpos anti-her2 monoclonales como agentes antitumorales. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1282440A1 (xx) |
| JP (1) | JP2003533490A (xx) |
| KR (1) | KR20030014223A (xx) |
| CN (1) | CN1429118A (xx) |
| AU (1) | AU784617B2 (xx) |
| BR (1) | BR0110732A (xx) |
| CA (1) | CA2409652A1 (xx) |
| CZ (1) | CZ20023748A3 (xx) |
| EA (1) | EA005931B1 (xx) |
| EE (1) | EE200200622A (xx) |
| HK (1) | HK1054200A1 (xx) |
| HU (1) | HUP0301877A2 (xx) |
| IL (1) | IL152389A0 (xx) |
| MX (1) | MXPA02011194A (xx) |
| NO (1) | NO20025302D0 (xx) |
| NZ (1) | NZ523004A (xx) |
| PL (1) | PL360153A1 (xx) |
| SK (1) | SK16022002A3 (xx) |
| WO (1) | WO2001087334A1 (xx) |
| ZA (1) | ZA200209815B (xx) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| EP1282443B1 (en) | 2000-05-19 | 2009-09-02 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| ES2269682T3 (es) * | 2001-01-26 | 2007-04-01 | Pfizer Italia S.R.L. | Exemestano para tratar transtornos que dependen de hormonas. |
| GB2375958B (en) | 2001-04-09 | 2005-03-02 | George Margetts | The use of steroids to lower the levels of cortisol |
| AU2003218600C1 (en) | 2002-03-26 | 2009-12-17 | Zensun (Shanghai) Science & Technology Co., Ltd. | ERBB3 based methods and compositions for treating neoplasms |
| CN1678348A (zh) * | 2002-07-01 | 2005-10-05 | 萨文特医药公司 | 用于治疗性治疗的组合物和方法 |
| FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| CN101014365B (zh) * | 2004-07-16 | 2011-04-13 | 辉瑞产品公司 | 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤 |
| UA94899C2 (ru) | 2005-01-21 | 2011-06-25 | Дженентек, Инк. | Фиксированное дозирование антител к her |
| EP1850874B1 (en) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| EP1945224B1 (en) | 2005-10-19 | 2012-05-02 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
| EP2132573B1 (en) | 2007-03-02 | 2014-04-23 | Genentech, Inc. | Predicting response to a her dimerisation inhbitor based on low her3 expression |
| DK2171090T3 (da) | 2007-06-08 | 2013-06-10 | Genentech Inc | Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| ES2572728T3 (es) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
| CA2761280A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| CN102892779B (zh) | 2010-02-18 | 2016-12-21 | 基因泰克公司 | 神经调节蛋白拮抗剂及其在治疗癌症中的用途 |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
| JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
| CN102068429B (zh) * | 2010-12-28 | 2011-12-14 | 西南大学 | 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法 |
| MX2014001766A (es) | 2011-08-17 | 2014-05-01 | Genentech Inc | Anticuerpos de neuregulina y sus usos. |
| WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
| CN106987620A (zh) | 2011-11-30 | 2017-07-28 | 霍夫曼-拉罗奇有限公司 | 癌症中的erbb3突变 |
| WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| JP2015514710A (ja) | 2012-03-27 | 2015-05-21 | ジェネンテック， インコーポレイテッド | Ｈｅｒ３阻害剤に関する診断及び治療 |
| US20160038490A1 (en) * | 2012-07-18 | 2016-02-11 | Angion Biomedica Corp. | Compositions and methods for treating dysproliferative diseases |
| WO2014083178A1 (en) | 2012-11-30 | 2014-06-05 | F. Hoffmann-La Roche Ag | Identification of patients in need of pd-l1 inhibitor cotherapy |
| US10064874B2 (en) | 2014-10-22 | 2018-09-04 | Havah Therapeutics Pty Ltd. | Methods of reducing mammographic breast density and/or breast cancer risk |
| AU2016343297A1 (en) | 2015-10-22 | 2018-05-10 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
| US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| CN107417791B (zh) * | 2017-08-17 | 2020-09-22 | 合肥瀚科迈博生物技术有限公司 | 抗人ErbB2双特异性抗体、其制备方法及用途 |
| CN119970752A (zh) | 2019-06-03 | 2025-05-13 | 哈瓦赫治疗有限公司 | 用于递送雄激素剂和芳香酶抑制剂的药物制剂 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
-
2001
- 2001-04-19 EP EP01929585A patent/EP1282440A1/en not_active Withdrawn
- 2001-04-19 MX MXPA02011194A patent/MXPA02011194A/es not_active Application Discontinuation
- 2001-04-19 CZ CZ20023748A patent/CZ20023748A3/cs unknown
- 2001-04-19 AU AU56309/01A patent/AU784617B2/en not_active Ceased
- 2001-04-19 HU HU0301877A patent/HUP0301877A2/hu unknown
- 2001-04-19 NZ NZ523004A patent/NZ523004A/en unknown
- 2001-04-19 PL PL36015301A patent/PL360153A1/xx not_active Application Discontinuation
- 2001-04-19 KR KR1020027015223A patent/KR20030014223A/ko not_active Ceased
- 2001-04-19 SK SK1602-2002A patent/SK16022002A3/sk not_active Application Discontinuation
- 2001-04-19 JP JP2001583801A patent/JP2003533490A/ja not_active Withdrawn
- 2001-04-19 WO PCT/EP2001/004468 patent/WO2001087334A1/en not_active Ceased
- 2001-04-19 HK HK03106504.3A patent/HK1054200A1/zh unknown
- 2001-04-19 BR BR0110732-1A patent/BR0110732A/pt not_active IP Right Cessation
- 2001-04-19 EE EEP200200622A patent/EE200200622A/xx unknown
- 2001-04-19 CA CA002409652A patent/CA2409652A1/en not_active Abandoned
- 2001-04-19 EA EA200201213A patent/EA005931B1/ru not_active IP Right Cessation
- 2001-04-19 IL IL15238901A patent/IL152389A0/xx unknown
- 2001-04-19 CN CN01809581A patent/CN1429118A/zh active Pending
-
2002
- 2002-11-05 NO NO20025302A patent/NO20025302D0/no not_active Application Discontinuation
- 2002-12-03 ZA ZA200209815A patent/ZA200209815B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK16022002A3 (sk) | 2003-04-01 |
| NO20025302L (no) | 2002-11-05 |
| HUP0301877A2 (hu) | 2003-09-29 |
| CN1429118A (zh) | 2003-07-09 |
| CZ20023748A3 (cs) | 2003-04-16 |
| EA200201213A1 (ru) | 2003-04-24 |
| AU5630901A (en) | 2001-11-26 |
| PL360153A1 (en) | 2004-09-06 |
| ZA200209815B (en) | 2003-12-03 |
| WO2001087334A1 (en) | 2001-11-22 |
| EP1282440A1 (en) | 2003-02-12 |
| EA005931B1 (ru) | 2005-08-25 |
| KR20030014223A (ko) | 2003-02-15 |
| JP2003533490A (ja) | 2003-11-11 |
| BR0110732A (pt) | 2003-02-04 |
| AU784617B2 (en) | 2006-05-18 |
| HK1054200A1 (zh) | 2003-11-21 |
| EE200200622A (et) | 2004-06-15 |
| NZ523004A (en) | 2004-09-24 |
| CA2409652A1 (en) | 2001-11-22 |
| NO20025302D0 (no) | 2002-11-05 |
| IL152389A0 (en) | 2003-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02011194A (es) | Inhibidores de aromatasa y anticuerpos anti-her2 monoclonales como agentes antitumorales. | |
| US20050032759A1 (en) | Antitumor combined therapy | |
| US6333348B1 (en) | Use of docetaxel for treating cancers | |
| AU2012229147B2 (en) | Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers | |
| JP2003504413A (ja) | 抗腫瘍物質を含む組み合わせ調製物 | |
| EP3042669A1 (en) | Antitumor agent and antitumor effect enhancer | |
| KR20180121571A (ko) | Liv1-adc와 화학요법제를 사용한 병용 요법 | |
| KR20200018785A (ko) | 유방암 치료를 위한 ErbB-2/ErbB-3 이중특이적 항체와 내분비 치료의 조합 | |
| Smith et al. | Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer | |
| Perry et al. | Trastuzumab | |
| CN113473989A (zh) | Sumo活化酶抑制剂和检查点抑制剂的施用 | |
| Tokuda et al. | Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan | |
| Cathomas et al. | Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib | |
| Nozawa et al. | Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study | |
| KR20230111071A (ko) | 렌바티닙을 포함하는 암의 방사면역치료 보조제 | |
| CN117281902A (zh) | 一种药物组合物在制备治疗黑色素瘤产品中的应用 | |
| NZ614427B2 (en) | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers | |
| NZ750260A (en) | Antitumor agent and antitumor effect enhancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |